Hypothesis

The persistent NAD+ decline observed in aging tissues is not a programmed downgrade of cellular ambition but a consequence of senescent cell–specific CD38 upregulation that consumes NAD+, thereby suppressing sirtuin activity and locking cells into a pro‑senescent state. Restoring NAD+ locally by inhibiting CD38 should re‑activate sirtuins, diminish the SASP, and sensitize senescent cells to Bcl‑2 family blockade.

Mechanistic rationale

1. Senescent cells exhibit elevated CD38 expression (see 4), which hydrolyzes NAD+ to ADP‑ribose and cyclic ADP‑ribose, depleting the pool available to SIRT1/6.
2. Low NAD+ reduces SIRT1 deacetylase activity, leading to hyperacetylation of p53 and NF‑κB, amplifying the SASP and reinforcing the senescent phenotype.
3. The SASP, in turn, fuels further CD38 expression via inflammatory signaling, creating a feed‑forward loop.
4. Pharmacologic CD38 inhibition (e.g., compound 78c) rescues NAD+ levels and extends lifespan in mice 5, suggesting that breaking this loop can counteract senescence.
5. Bcl‑2 family inhibitors (venetoclax, S63845) efficiently eliminate senescent cells when anti‑apoptotic dependencies are met 12, but their efficacy varies across cell types because some senescent cells rely on MCL‑1 while others depend on BCL‑XL or BCL‑2.

Testable prediction

If CD38‑driven NAD+ loss sustains senescence, then combining a CD38 inhibitor with a dual Bcl‑2/MCL‑1 inhibitor will produce synergistic senolysis that is greater than the sum of each monotherapy, and this effect will be abolished in SIRT1‑deficient cells.

Experimental design (outline)

• Use naturally aged mice (24 mo) treated with: (a) vehicle, (b) 78c alone, (c) venetoclax + S63845 alone, (d) triple combination.
• Quantify senescent cell burden via p16^Ink4a^ immunostaining and SA‑β‑gal activity in liver, kidney, and adipose tissue.
• Measure tissue NAD+ levels, SIRT1 activity, and SASP cytokines (IL‑6, IL‑1β, TNF‑α).
• In parallel, isolate primary senescent human fibroblasts, treat with the same regimens, and assess viability and SASP suppression; repeat with SIRT1 knock‑down via siRNA to test dependency.

Falsifiability

If the triple combination does not reduce senescent cell burden more than the Bcl‑2 inhibitor pair alone, or if NAD+ restoration fails to lower SASP despite CD38 inhibition, the hypothesis that CD38‑mediated NAD+ depletion is a driver of senescent persistence would be refuted. Conversely, a significant additive/synergistic decrease in senescence markers, coupled with restored SIRT1 activity, would support the model.